

Medical drug benefit *Clinical Criteria* updates

On May 15, 2020, June 18, 2020, August 21, 2020, and September 24, 2020, the Pharmacy and Therapeutics (P&T) Committee approved the following *Clinical Criteria* applicable to the **medical drug benefit** for Anthem Blue Cross and Blue Shield. These policies were developed, revised or reviewed to support clinical coding edits.

Visit [Clinical Criteria](#) to search for specific policies. If you have questions or would like additional information, use this [email](#).

Please see the explanation/definition for each category of *Clinical Criteria* below:

- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive

Please share this notice with other members of your practice and office staff.

Note: The *Clinical Criteria* listed below applies only to the medical drug benefits contained within the member's medical policy. This does not apply to pharmacy services.

Effective date	Document number	<i>Clinical Criteria</i> title	New or revised
July 29, 2021	ING-CC-0162*	Tepezza (teprotumumab-trbw)	New
July 29, 2021	ING-CC-0163*	Durysta (bimatoprost implant)	New
July 29, 2021	ING-CC-0164*	Jelmyto (mitomycin gel)	New
July 29, 2021	ING-CC-0165*	Trodelyv (sacituzumab govitecan)	New
July 29, 2021	ING-CC-0166*	Trastuzumab Agents Step Therapy	New
July 29, 2021	ING-CC-0167*	Rituximab Agents for Oncologic Indications	New
July 29, 2021	ING-CC-0169*	Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)	New
July 29, 2021	ING-CC-0170*	Uplizna (inebilizumab-cdon)	New
July 29, 2021	ING-CC-0171*	Zepzelca (lurbinectedin)	New
July 29, 2021	ING-CC-0173*	Enspryng (satralizumab-mwge)	New
July 29, 2021	ING-CC-0174*	Kesimpta (ofatumumab)	New
July 29, 2021	ING-CC-0175*	Proleukin (aldesleukin)	New
July 29, 2021	ING-CC-0176*	Beleodaq (belinostat)	New
July 29, 2021	ING-CC-0177*	Zilretta (triamcinolone acetone extended-release)	New
July 29, 2021	ING-CC-0178*	Synribo (omacetaxine mepesuccinate)	New
July 29, 2021	ING-CC-0179*	Blenrep (belantamab mafodotin-blmf)	New
July 29, 2021	ING-CC-0180*	Monjuvi (tafasitamab-cxix)	New

www.anthem.com/inmedicaiddoc

Anthem Blue Cross and Blue Shield is the trade name of Anthem Insurance Companies, Inc., independent licensee of the Blue Cross and Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

Providers who are contracted with Anthem Blue Cross and Blue Shield to serve Hoosier Healthwise, Healthy Indiana Plan and Hoosier Care Connect through an accountable care organization (ACO), participating medical group (PMG) or Independent Physician Association (IPA) are to follow guidelines and practices of the group. This includes but is not limited to authorization, covered benefits and services, and claims submittal. If you have questions, please contact your group administrator or your Anthem network representative.

July 29, 2021	ING-CC-0001*	Erythropoiesis Stimulating Agents	Revised
July 29, 2021	ING-CC-0002*	Colony Stimulating Factor Agents	Revised
July 29, 2021	ING-CC-0009*	Lemtrada (alemtuzumab) for the Treatment of Multiple Sclerosis	Revised
July 29, 2021	ING-CC-0010*	Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors	Revised
July 29, 2021	ING-CC-0011*	Ocrevus (ocrelizumab)	Revised
July 29, 2021	ING-CC-0014*	Beta Interferons and Glatiramer Acetate for Treatment of Multiple Sclerosis	Revised
July 29, 2021	ING-CC-0017*	Xiaflex (collagenase clostridium histolyticum)	Revised
July 29, 2021	ING-CC-0019*	Zoledronic Acid Agents	Revised
July 29, 2021	ING-CC-0021*	Fabrazyme (agalsidase beta)	Revised
July 29, 2021	ING-CC-0022*	Vimizim (elosulfase alfa)	Revised
July 29, 2021	ING-CC-0023*	Naglazyme (galsulfase)	Revised
July 29, 2021	ING-CC-0024*	Elaprase (idursulfase)	Revised
July 29, 2021	ING-CC-0025*	Aldurazyme (laronidase)	Revised
July 29, 2021	ING-CC-0027*	Denosumab Agents	Revised
July 29, 2021	ING-CC-0029	Dupixent (dupilumab)	Revised
July 29, 2021	ING-CC-0035*	Duopa (carbidopa and levodopa enteral suspension)	Revised
July 29, 2021	ING-CC-0038*	Human Parathyroid Hormone Agents	Revised
July 29, 2021	ING-CC-0042	Monoclonal Antibodies to Interleukin-17	Revised
July 29, 2021	ING-CC-0050	Monoclonal Antibodies to Interleukin-23	Revised
July 29, 2021	ING-CC-0051	Enzyme Replacement Therapy for Gaucher Disease	Revised
July 29, 2021	ING-CC-0058*	Ocotride Agents (Byngezia Pen, Sandostatin, or Sandostatin LAR)	Revised
July 29, 2021	ING-CC-0062*	Tumor Necrosis Factor Antagonists	Revised
July 29, 2021	ING-CC-0063	Stelara (ustekinumab)	Revised
July 29, 2021	ING-CC-0064	Interleukin-1 Inhibitors	Revised
July 29, 2021	ING-CC-0072	Selective VEGF Antagonists	Revised
July 29, 2021	ING-CC-0077*	Palynziq (pegvaliase-pqpz)	Revised
July 29, 2021	ING-CC-0081	Crysvita (burosumab-twza)	Revised
July 29, 2021	ING-CC-0082*	Onpattro (patisiran)	Revised
July 29, 2021	ING-CC-0084*	Tegsedi (inotersen)	Revised
July 29, 2021	ING-CC-0094*	Alimta (pemetrexed disodium)	Revised
July 29, 2021	ING-CC-0099*	Abraxane (paclitaxel, protein bound)	Revised
July 29, 2021	ING-CC-0104	Levoleucovorin Agents	Revised
July 29, 2021	ING-CC-0107*	Bevacizumab for Non-Ophthalmologic Indications	Revised
July 29, 2021	ING-CC-0111	Nplate (romiplostim)	Revised
July 29, 2021	ING-CC-0119*	Yervoy (ipilimumab)	Revised
July 29, 2021	ING-CC-0124	Keytruda (pembrolizumab)	Revised
July 29, 2021	ING-CC-0125*	Opdivo (nivolumab)	Revised
July 29, 2021	ING-CC-0127*	Darzalex (daratumumab) and Darzalex Faspro (daratumumab and hyaluronidase-fihj)	Revised
July 29, 2021	ING-CC-0128*	Tecentriq (atezolizumab)	Revised
July 29, 2021	ING-CC-0129	Bavencio (avelumab)	Revised
July 29, 2021	ING-CC-0132	Mylotarg (gemtuzumab ozogamicin)	Revised
July 29, 2021	ING-CC-0139	Evenity (romosozumab-aqqg)	Revised
July 29, 2021	ING-CC-0156	Reblozyl (luspatercept)	Revised
July 29, 2021	ING-CC-0160*	Vyepti (eptinezumab)	Revised

